{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:06:57Z","timestamp":1784920017396,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Research & Development, LLC, a Johnson & Johnson Company"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Purpose<\/jats:title>\n Prostatitis has been reported in patients with type 2 diabetes mellitus (T2DM) receiving antihyperglycemic agents (AHAs). This study was conducted to evaluate the risk of prostatitis with canagliflozin in response to a specific Health Authority query.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study used data from adult male patients with T2DM who were new users of canagliflozin (target) or comparators (empagliflozin, dapagliflozin, sitagliptin, and liraglutide). Data were obtained from 8 global administrative claims databases, transformed to a Common Data Model for consistent analysis across databases. Pairwise comparisons were conducted using propensity scores to match canagliflozin users to users of each comparator at a 1:n ratio (maximum n\u2009=\u2009100). Hazard ratios were estimated using a Cox proportional hazards model, conditioned on the matched set.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 388,893 adult male patients with T2DM received canagliflozin across databases (mean age, 51.2\u201371.7 years) and were matched to 657,134 patients receiving empagliflozin, 340,539 receiving dapagliflozin, 819,047 receiving sitagliptin, and 278,684 receiving liraglutide. On-treatment incidence rates showed that prostatitis was uncommon in the canagliflozin cohort in nearly all databases (4.2\u20137.7 per 1000 person-years) and were similar to those of the comparator treatments. The exception was a higher crude incidence rate in the Merative MarketScan\n \u00ae<\/jats:sup>\n Medicare Supplemental Database (10.1\u201312.1 per 1000 person-years). Propensity score matching achieved good balance in all available covariates, and effect estimates were relatively close to a hazard ratio of 1.0, varying on both sides of the null effect. Minimum detectable relative risks were low in most databases, and meta-analytic estimates were near 1.0, with all upper bounds <1.50. No association (either increased or decreased risk) was found with canagliflozin versus other AHAs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This analysis found no evidence of a statistically significantly increased risk of prostatitis among adult male patients with T2DM receiving canagliflozin compared with the other AHAs evaluated in this study.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0341745","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:22:22Z","timestamp":1770056542000},"page":"e0341745","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-2040","authenticated-orcid":true,"given":"Zhong","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"Jeffcoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1581-8431","authenticated-orcid":true,"given":"Saberi Rana","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-5347","authenticated-orcid":true,"given":"Anthony G.","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"12","key":"pone.0341745.ref001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/psb.1521","article-title":"SGLT2 inhibitors and risk of genitourinary infections","volume":"27","author":"S Chaplin","year":"2016","journal-title":"Prescriber"},{"issue":"3","key":"pone.0341745.ref002","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"S Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"pone.0341745.ref003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1099\/00222615-48-6-535","article-title":"Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals","volume":"48","author":"SE Geerlings","year":"1999","journal-title":"J Med Microbiol"},{"issue":"3","key":"pone.0341745.ref004","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7883\/yoken.JJID.2008.236","article-title":"Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus","volume":"61","author":"H Turan","year":"2008","journal-title":"Jpn J Infect Dis"},{"key":"pone.0341745.ref005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0924-8579(03)00234-6","article-title":"Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus","author":"AIM Hoepelman","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0341745.ref006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11908-013-0389-2","article-title":"Urinary tract infection in diabetes: epidemiologic considerations","volume":"16","author":"V de Lastours","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"pone.0341745.ref007","first-page":"129","article-title":"Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management","volume":"8","author":"O Nitzan","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"pone.0341745.ref008","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/1573399812666161019162747","article-title":"Genitourinary complications of diabetes mellitus: an overview of pathogenesis, evaluation, and management","volume":"13","author":"J Gandhi","year":"2017","journal-title":"Curr Diabetes Rev"},{"issue":"22","key":"pone.0341745.ref009","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.3390\/jcm12226993","article-title":"Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the KAMOGAWA-A study","volume":"12","author":"Y Saijo","year":"2023","journal-title":"J Clin Med"},{"key":"pone.0341745.ref010","article-title":"SGLT2 inhibitors for type 2 diabetes mellitus treatment","volume":"32","author":"RA Plodkowski","year":"2015","journal-title":"Fed Pract"},{"issue":"2","key":"pone.0341745.ref011","article-title":"Sodium-glucose co-transporter-2 inhibitors causing Candida tropicalis fungemia and renal abscess","volume":"2","author":"PK Simhadri","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"1","key":"pone.0341745.ref012","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12879-021-05982-3","article-title":"Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports","volume":"21","author":"C Bartolo","year":"2021","journal-title":"BMC Infect Dis"},{"key":"pone.0341745.ref013","doi-asserted-by":"crossref","first-page":"2042098621997703","DOI":"10.1177\/2042098621997703","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes","volume":"12","author":"N Varshney","year":"2021","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"pone.0341745.ref014","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"R Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"issue":"1","key":"pone.0341745.ref015","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"J Liu","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0341745.ref016","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers","volume":"216","author":"G Hripcsak","year":"2015","journal-title":"Stud Health Technol Inform"},{"issue":"3","key":"pone.0341745.ref017","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jamia\/ocu023","article-title":"Feasibility and utility of applications of the common data model to multiple, disparate observational health databases","volume":"22","author":"EA Voss","year":"2015","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"pone.0341745.ref018","article-title":"CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterization","volume":"20","author":"GA Rao","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"pone.0341745.ref019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/sim.5925","article-title":"Interpreting observational studies: why empirical calibration is needed to correct p-values","volume":"33","author":"MJ Schuemie","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"pone.0341745.ref020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Y Tian","year":"2018","journal-title":"Int J Epidemiol"},{"key":"pone.0341745.ref021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","author":"JA Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0341745.ref022","doi-asserted-by":"crossref","first-page":"104204","DOI":"10.1016\/j.jbi.2022.104204","article-title":"Adjusting for indirectly measured confounding using large-scale propensity score","volume":"134","author":"L Zhang","year":"2022","journal-title":"J Biomed Inform"},{"key":"pone.0341745.ref023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CER.S40357","article-title":"A tool for assessing the feasibility of comparative effectiveness research","volume":"3","author":"AM Walker","year":"2013","journal-title":"Comparat Effect Res"},{"issue":"3","key":"pone.0341745.ref024","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/09622802211060518","article-title":"Combining cox regressions across a heterogeneous distributed research network facing small and zero counts","volume":"31","author":"MJ Schuemie","year":"2022","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"pone.0341745.ref025","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1097\/01.ju.0000182152.28519.e7","article-title":"Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community","volume":"174","author":"JQ Clemens","year":"2005","journal-title":"J Urol"},{"issue":"4","key":"pone.0341745.ref026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"CV Dave","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0341745.ref027","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dom.14082","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study","volume":"22","author":"A Fisher","year":"2020","journal-title":"Diabetes Obes Metab"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:22:27Z","timestamp":1770056547000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341745"}},"subtitle":[],"editor":[{"given":"Marwan Salih","family":"Al-Nimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341745","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}